News

Printer Friendly Version View printer-friendly version
<< Back
Array BioPharma Appoints Gil Van Lunsen From KPMG to Its Board of Directors
BOULDER, Colo., Oct 31, 2002 /PRNewswire-FirstCall via COMTEX/ --

- Array Reorganizes Board Committees -

Array BioPharma Inc. (Nasdaq: ARRY) today announced the appointment of Gil J. Van Lunsen to its Board of Directors, and chair of the Board's Audit Committee. His appointment is effective October 31. Mr. Van Lunsen replaces Robert W. Overell, Ph.D., who served on Array's Board since December, 1999 and resigned from the Board effective October 31, 2002.

Mr. Van Lunsen brings over 33 years of auditing and accounting experience to Array's Board. He was formerly a Managing Partner of KPMG, where he retired in 2000. In addition, Mr. Van Lunsen has served on six external boards, including as Chair of two audit committees and Chair of two boards of trustees.

"I am very pleased to announce the appointment of Mr. Van Lunsen, whose financial accounting expertise will be a great asset as we grow our company," said Kyle Lefkoff, Chairman, Array BioPharma Board of Directors. "As a seasoned auditor and a senior executive, Mr. Van Lunsen will provide valuable knowledge and leadership to our Board and our Audit Committee."

Mr. Van Lunsen began his career at KPMG in 1968 in Accounting. Over time, he assumed positions of increasing responsibility including Senior Manager and Audit Partner. Most recently, he led the firm's Tulsa, Oklahoma office, serving clients in the energy, industrial products, food products and venture capital industries. In addition to his work at KPMG, Mr. Van Lunsen serves on external boards. Presently, he is the Audit Committee Chairman at both Hillcrest Healthcare System in Tulsa, Oklahoma and VariL Company, Inc. in Denver, Colorado. Additionally, Mr. Van Lunsen is a member on the Ethics Compliance Committee for Tyson Foods, Inc. in Springdale, Arkansas.

"I am pleased to have the opportunity to contribute to the growth of Array BioPharma," said Mr. Van Lunsen. "This company continues to make tremendous progress, and I look forward to being part of the team going forward."

In filling the vacancy arising from Dr. Overell's resignation, Mr. Van Lunsen will serve the remainder of Dr. Overell's term as a Class I director, which expires at the annual shareholders meeting in 2004.

Additionally, Array's Board of Directors announced the reorganization of the Audit, Compensation and Corporate Governance Committees as shown below. These committee members are all outside directors.

Audit Committee -- Chair Gil J. Van Lunsen
Kirby L. Cramer
John L. Zabriskie, Ph.D.

Compensation Committee -- Chair Kyle Lefkoff
Francis J. Bullock, Ph.D.
Marvin H. Caruthers, Ph.D.

Governance Committee -- Chair John L. Zabriskie, Ph.D.
Francis J. Bullock, Ph.D.
Kyle Lefkoff

About Array BioPharma:

Array BioPharma is a drug discovery company creating new small molecule drugs through the integration of chemistry, biology and informatics. Our experienced scientists use an integrated set of drug discovery technologies, which we call the Array Discovery Platform, to invent small molecule drugs in collaboration with leading pharmaceutical and biotechnology companies and to build our own pipeline of proprietary drug candidates. For more information on Array BioPharma, please visit our web site at www.arraybiopharma.com .

SOURCE Array BioPharma Inc.

CONTACT: Tricia Haugeto of Array BioPharma Inc., +1-303-386-1193, thaugeto@arraybiopharma.com